Study for treatment of untreated Acute Myeloid Leukemia (AML)

This study is open to adults age 18 to 60 years.

Primary disease category: Cancer

Secondary disease categories: Leukemia & Lymphoma

Sponsor: Southwest Oncology Group

Protocol number: S1203

Projected enrollment dates: January 2014 to January 2019

Official study title: A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)